Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials
- PMID: 18556397
- PMCID: PMC3936673
- DOI: 10.1097/JGP.0b013e318172b406
Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials
Abstract
Objective: Among Alzheimer disease (AD) patients enrolled in a clinical trial, the authors assessed the ability of a standardized capacity assessment procedure to identify persons who are capable of giving their own informed consent.
Design: Cross-sectional interview.
Setting: Thirteen sites participating in a randomized and placebo controlled study of simvastatin for the treatment of mild to moderate AD.
Participants: Persons with mild to moderate AD and their study partners enrolled in the simvastatin clinical trial.
Measurements: Interviews to assess decision-making capacity using the MacArthur Competency Assessment Tool for Clinical Research (MacCAT-CR).
Results: Judges blinded to the subject's clinical status had a high rate of agreement on patients capable of giving their own informed consent (kappa = 0.73). The understanding subscale had the best receiver operator characteristic and an analysis of positive and negative predictive values over a range of hypothetical prevalences of incapacity to consent demonstrated the value of a range of understanding cut-points.
Conclusion: Among mild to moderate AD patients, enrolled in an actual clinical trial, these results suggest evidence based guidelines for using the MacCAT-CR understanding subscale to help guide judgments about whether a patient has the capacity to consent.
Conflict of interest statement
Dr. Marson and Dr. Kim report no conflicts of interest.
References
-
- Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111–1116. - PubMed
-
- Schulz R, Mendelsohn AB, Haley WE, et al. End-of-life care and the effects of bereavement on family caregivers of persons with dementia. N Engl J Med. 2003;349:1936–1942. - PubMed
-
- Schulz R, O’Brien A, Bookwala J, et al. Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist. 1995;35:771–791. - PubMed
-
- Gauthier S. Do we have a treatment for Alzheimer Disease? Yes Arch Neurol. 1999;56:738–739. - PubMed
-
- Pryse-Phillips W. Do we have drugs for dementia? No Arch Neurol. 1999;56:735–737. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
